Cagrilintide Tirzepatide (peptidedosingprotocols.com)

How it works

The cagrilintide + tirzepatide stack combines two peptides that target different pathways involved in appetite regulation and metabolic processes. Tirzepatide is a dual GLP-1 and GIP agonist, which means it activates two key receptors in the body. The GLP-1 receptor is known for its role in suppressing appetite and slowing gastric emptying, while the GIP receptor enhances insulin sensitivity and metabolic efficiency. This dual action makes tirzepatide a powerful agent for weight loss and metabolic health, as evidenced by its FDA approval for obesity and type 2 diabetes.

However, tirzepatide does not activate amylin receptors, which are crucial for signaling satiety in the brain. Amylin, a hormone released by the pancreas, communicates to the brain that the body has had enough food. By adding cagrilintide, a long-acting amylin analog, the stack introduces a third mechanism for appetite suppression. This combination allows for appetite regulation through two distinct pathways in the brain, enhancing the overall effectiveness of the treatment.

Preclinical studies, such as the one conducted by Valdecantos et al. (ADA 2024), have shown that the combination of cagrilintide and tirzepatide leads to greater weight loss in obese rats compared to either compound alone. This suggests a synergistic effect when both peptides are used together, although it is important to note that human trials have not yet been conducted to confirm these findings.

Both peptides also slow gastric emptying, which can prolong the feeling of fullness after meals. However, this overlapping effect can increase the risk of gastrointestinal side effects such as nausea and constipation, which is why a staggered titration approach is recommended. Starting with tirzepatide alone allows for the establishment of gastrointestinal tolerance before introducing cagrilintide at a low dose. This careful approach aims to maximize the benefits of the stack while minimizing potential adverse effects. [Source: Peptide Dosing Protocols]

Plain language: The stack works by combining tirzepatide, which reduces appetite and improves insulin sensitivity, with cagrilintide, which signals fullness, enhancing weight loss through multiple pathways.

Who should avoid it

Individuals with active gastrointestinal disease should avoid this stack due to the potential for exacerbated GI symptoms. Those with type 1 diabetes are also advised against using this combination, as it may lead to complications. A history of pancreatitis is another contraindication, as tirzepatide carries a class warning for this condition. Additionally, individuals with a history of medullary thyroid carcinoma or active cancer should not use this stack, as the safety profile in these populations has not been established. The addition of cagrilintide raises the GI tolerance requirements, making it even more critical for these groups to avoid this combination. [Source: Peptide Dosing Protocols]

Plain language: People with certain medical conditions like active gastrointestinal disease, type 1 diabetes, or a history of pancreatitis should avoid this stack.